Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans

Patrick Starlinger, Alice Assinger, Stefanie Haegele, David Wanek, Silvia Zikeli, Dominic Schauer, Peter Birner, Edith Fleischmann, Birgit Gruenberger, Christine Brostjan, Thomas Gruenberger – 26 November 2013 – Liver regeneration (LR) involves a complex interplay of growth factors and antagonists. In this context, platelet‐derived serotonin (5‐HT) has been identified as a critical inducer of LR in mice. Clinical evidence for a role of 5‐HT in LR in humans is lacking.

Risk factors for alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan

Hiroto Egawa, Katsuji Nishimura, Satoshi Teramukai, Masakazu Yamamoto, Koji Umeshita, Hiroyuki Furukawa, Shinji Uemoto – 25 November 2013 – Alcoholic liver cirrhosis (ALC) is an established indication for liver transplantation (LT). Most LT procedures in Japan are living donor liver transplantation (LDLT) because of an extreme shortage of deceased donors. Social circumstances enabling LDLT could be favorable for preventing relapse. The aims of this retrospective study were to analyze the outcomes of LDLT for ALC and to evaluate risk factors for relapse in this cohort.

Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early‐stage hepatocellular carcinoma

Kaoru Tsuchiya, Yasuhiro Asahina, Nobuharu Tamaki, Yutaka Yasui, Takanori Hosokawa, Ken Ueda, Hiroyuki Nakanishi, Jun Itakura, Masayuki Kurosaki, Nobuyuki Enomoto, Namiki Izumi – 25 November 2013 – Radiofrequency ablation (RFA) is an effective and safe noninvasive treatment for hepatocellular carcinoma (HCC) and may be useful as a bridging therapy in liver transplantation. The prognosis after liver transplantation for patients within the Milan criteria is excellent.

Hepatocyte transplantation using a living donor reduced graft in a baby with ornithine transcarbamylase deficiency: A novel source of hepatocytes

Shin Enosawa, Reiko Horikawa, Akiko Yamamoto, Seisuke Sakamoto, Takanobu Shigeta, Shunsuke Nosaka, Junichiro Fujimoto, Akito Tanoue, Kazuaki Nakamura, Akihiro Umezawa, Yoichi Matsubara, Akira Matsui, Mureo Kasahara – 23 November 2013

FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis

Chunjiong Wang, Yujing Chi, Jing Li, Yifei Miao, Sha Li, Wen Su, Shi Jia, Zhenzhen Chen, Shengnan Du, Xiaoyan Zhang, Yunfeng Zhou, Wenhan Wu, Mingyan Zhu, Zhiwei Wang, Huaqian Yang, Guoheng Xu, Shiqiang Wang, Jichun Yang, Youfei Guan – 23 November 2013 – FAM3A belongs to a novel cytokine‐like gene family, and its physiological role remains largely unknown. In our study, we found a marked reduction of FAM3A expression in the livers of db/db and high‐fat diet (HFD)‐induced diabetic mice.

Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats

Elena Grossini, Piero Pollesello, Kevin Bellofatto, Lorenzo Sigaudo, Serena Farruggio, Veronica Origlia, Cristina Mombello, David A. S. G. Mary, Guido Valente, Giovanni Vacca – 23 November 2013 – As in other organs, oxidative stress–induced injury and cell death may result from free oxygen radical–dependent mechanisms and alterations in signal transduction pathways leading to apoptosis. Among the new suggested therapies for injuries caused by oxidative stress, the use of levosimendan has been reported to be quite promising.

Subscribe to